Blood test identifies HPV-associated head and neck cancers up to 10 years before symptoms

(Press-News.org) Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical cancers caused by HPV, there is no screening test for HPV-associated head and neck cancers. This means that patients are usually diagnosed after a tumor has grown to billions of cells in size, causing symptoms and spreading to lymph nodes. Screening methods that can detect these cancers much earlier could mean earlier treatment interventions for patients. 

In a new federally funded study, published in the Journal of the National Cancer Institute, Mass General Brigham researchers show that a novel liquid biopsy tool they developed, called HPV-DeepSeek, can identify HPV-associated head and neck cancer up to 10 years before symptoms appear. By catching cancers earlier with this novel test, patients may experience higher treatment success and require a less intense regimen, according to the authors.  

“Our study shows for the first time that we can accurately detect HPV-associated cancers in asymptomatic individuals many years before they are ever diagnosed with cancer,” said lead study author Daniel L. Faden, MD, FACS, a head and neck surgical oncologist and principal investigator in the Mike Toth Head and Neck Cancer Research Center at Mass Eye and Ear, a member of the Mass General Brigham healthcare system. “By the time patients enter our clinics with symptoms from the cancer, they require treatments that cause significant, life-long side effects. We hope tools like HPV-DeepSeek will allow us to catch these cancers at their very earliest stages, which ultimately can improve patient outcomes and quality of life.”  

HPV-DeepSeek uses whole-genome sequencing to detect microscopic fragments of HPV DNA that have broken off from a tumor and entered the bloodstream. Previous research from this team showed the test could achieve 99% specificity and 99% sensitivity for diagnosing cancer at the first time of presentation to a clinic, outperforming current testing methods. 

To determine whether HPV-DeepSeek could detect HPV-associated head and neck cancer long before diagnosis, researchers tested 56 samples from the Mass General Brigham Biobank: 28 from individuals who went on to develop HPV-associated head and neck cancer years later, and 28 from healthy controls. 

HPV-DeepSeek detected HPV tumor DNA in 22 out of 28 blood samples from patients who later developed the cancer, whereas all 28 control samples tested negative, indicating that the test is highly specific. The test was better able to detect HPV DNA in blood samples that were collected closer to the time of the patients’ diagnosis, and the earliest positive result was for a blood sample collected 7.8 years prior to diagnosis. 

Using machine learning, the researchers were able to improve the test’s power so that it accurately identified 27 out of 28 cancer cases, including samples collected up to 10 years prior to diagnosis.  

The authors are now validating these findings in a second blinded study funded by the National Institutes of Health (NIH) using hundreds of samples collected as part of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) at the National Cancer Institute. 

### 

Authorship: In addition to Faden, study co-authors at Mass General Brigham include Dipon Das, Shun Hirayama, Ling Aye, Michael E. Bryan, Saskia Naegele, Brian Zhao, Vasileios Efthymiou, Julia Mendel, Adam S. Fisch, Zoe Guan, Jeremy D. Richmon, Michael S. Lawrence, Matthew G. Crowson, and John Iafrate. Additional co-authors include Lea Kröller, Birgitta E. Michels, Tim Waterboer, and Viktor Adalsteinsson.  

Disclosures: Faden receives salary support from NIH/NIDCR K23 DE029811, NIH/NIDCR R03 DE030550 and NIH/NCI R21 CA267152. He has also received research funding or in-kind funding from Bristol-Myers Squibb, Calico, Predicine, BostonGene, Neogenomics and Haystack (Quest), in addition to consulting fees from Merck, Noetic, Chrysalis Biomedical Advisors, Neogenomics, Arcadia, and Focus. None of these sources relate to the work in this manuscript. Waterboer serves on advisory boards for Merck (MSD) Sharp & Dohme. The remaining authors have declared no conflicts of interest. 
 
Funding: Funding for this work came from the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH), grant no. R03DE030550. 

Paper cited: Das, D et al. “Circulating tumor HPV DNA whole genome sequencing enables HPV-associated oropharynx cancer early detection” JNCI DOI: 10.1093/jnci/djaf249

### 

About Mass General Brigham 

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org. 

END